Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 15/20 | 1.00 |
| ▸ | PDE1A | P54750 | 11/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 11/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 11/20 | 1.00 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 1.00 |
| ▸ | PDE5A | O76074 | 4/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113961 | 0.88 | PDE7A (0.79) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL20694154 | 0.87 | PDE7A (0.78) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL4252304 | 0.86 | PDE7A (0.78) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL5521839 | 0.86 | PDE7A (0.75) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL5102984 | 0.82 | PDE7A (0.73) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL4257975 | 0.82 | PDE7A (0.84) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL5109597 | 0.81 | PDE7A (0.82) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3952384 | 0.81 | PDE7A (1.00) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL8245267 | 0.81 | PDE7A (1.00) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL4253220 | 0.81 | PDE7A (0.75) | PDE7APDE4DPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005089515-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2019-06-20 | — | — | US | disclosed |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2019-05-09 | — | — | US | disclosed |
| EP-2427193-B1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORP (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-9220715-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-9119822-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2013176877-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2013-10-10 | — | — | US | disclosed |
| WO-2012064667-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2010129036-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2008119057-A2 | THE USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| US-7429598-B2 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1542694-A1 | NEW SPIROCONDENSED QUINAZOLINONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040106631-A1 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-06-03 | — | — | US | disclosed |
| WO-2004026818-A1 | NEW SPIROCONDENSED QUINAZOLINONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1400244-A1 | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | Warner-Lambert Company LLC (US) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | PDE7A 3/4885PDE4D 16/4885PDE1A 14/4885 |
| US-20040106631-A1 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | PDE3A, PDE5A, PDE3B | PDE7A 21/4885PDE4D 12/4885PDE1A 29/4885 |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | PDE7A 3/4885PDE4D 16/4885PDE1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.